Biora Therapeutics, Inc. Asset Resilience Ratio
Biora Therapeutics, Inc. asset resilience ratio. Biora Therapeutics, Inc. (BIORQ) has an Asset Resilience Ratio of 17.35% as of December 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BIORQ defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biora Therapeutics, Inc. (2018–2018)
Asset resilience ratio of Biora Therapeutics, Inc. from 2018 to 2018. This chart shows how Biora Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Read total liabilities of Biora Therapeutics, Inc. for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Biora Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BIORQ current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $20.20 Million | 17.35% |
| Total Liquid Assets | $20.20 Million | 17.35% |
Asset Resilience Insights
- Good Liquidity Position: Biora Therapeutics, Inc. maintains a healthy 17.35% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Biora Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Biora Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Biora Therapeutics, Inc. Asset Resilience Ratio by Year (2018–2018)
Biora Therapeutics, Inc. asset resilience ratio by year from 2018 to 2018. The table below shows the annual Asset Resilience Ratio data for Biora Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 17.35% | $20.20 Million | $116.40 Million | -- |
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-fre… Read more